IP‑MS Data Analysis Workflow: Filtering, Normalization, Statistics, and Confident Hits

IP‑MS isn't hard because the plots are fancy; it's hard because enrichment lives on top of background. This guide makes ip‑ms data analysis repeatable by centering the comparison to your negative control and pairing effect size with the false discovery rate (FDR). We'll walk from raw intensities to confident hits—with a QC‑first mindset, background‑aware filtering, principled normalization, transparent handling of missing values, and statistics you can defend to reviewers.

Key takeaways

• Define a "hit" up front: enriched versus negatives, with adequate effect size and BH‑controlled FDR, and consistent across replicates.
• Treat IgG as the primary negative; use beads‑only and KO/untagged as sensitivity checks to probe robustness.
• QC triage comes first: check replicate agreement, control sanity, and batch structure before any thresholds.
• Filter with context: remove obvious contaminants, but lean on negatives/CRAPome concepts rather than global blacklists.
• Normalize to improve comparability, not to rescue poor experiments; watch for signs of over‑normalization.
• Package results for publication: an annotated volcano, three auditable tables, and wording that explains assumptions and sensitivity.

Why IP‑MS data analysis feels hard (and how to make it routine)

IP‑MS differs from discovery proteomics in one decisive way: success isn't "the most proteins," it's "the right proteins enriched over background." Background is complicated—antibody cross‑reactivity, bead binders, and sticky proteins all contribute—and it is experiment‑specific. The antidote is a workflow that treats negative controls as first‑class citizens at every step, records assumptions, and exposes sensitivity to reasonable alternatives. Do this, and IP‑MS becomes routine instead of fragile.

For study planning and control design specifics, see IP‑MS workflow design: controls and replicates planning.

What makes IP‑MS different from standard proteomics

• Signal is defined by bait‑dependent enrichment, not presence/absence alone.
• Negatives (IgG, beads‑only, KO/untagged) quantify experiment‑specific background.
• Classic interactome scoring frameworks formalize these ideas by contrasting bait runs to controls and weighting reproducibility or background frequency—see SAINT, CompPASS, and MiST for canonical examples in the literature: SAINT probabilistic scoring (Nat Methods, 2011), CompPASS (PNAS, 2009), and MiST protocol overview (Curr Protoc Bioinf, 2015).

Inputs you need before analysis (avoid rework)

Before you touch statistics, assemble complete metadata and define what "good" looks like. A few minutes here saves days later.

Metadata checklist (sample groups, controls, batches)

• Bait identity and tag; sample groups and replicate structure (biological/technical)
• Negative control plan: IgG (primary), beads‑only (matrix background), KO/untagged (strongest negative if available)
• Batch/run annotations and acquisition mode (DDA/DIA); instrument/date
• Any spike‑ins or internal references intended for normalization
• Pre‑specified decision logic (effect size + BH‑FDR) and sensitivity plan

If you're still planning the experiment, see the design principles in the IP‑MS workflow design: controls and replicates planning.

What file types/outputs typically enter analysis

You'll typically feed: protein‑level intensities or spectral counts as the main matrix; peptide/PSM evidence (for provenance and optional weighting); search‑engine FDR summaries; and run‑level QC logs. Keep raw‑to‑report traceability so any reviewer can re‑compute summaries.

Define your "hit" concept before you look at a volcano plot

Write it down: a hit is enriched versus negative controls by a meaningful log2 fold change, reaches a multiple‑testing‑adjusted significance (e.g., BH‑FDR), and shows replicate consistency. The volcano is a communication device, not the decision engine.

IP‑MS data analysis workflow: QC triage, background‑aware filtering, normalization, missing value handling, statistics with FDR, and confident hits.

Step 1 — Basic QC triage: do not analyse broken data

Think of this as a safety inspection: if replicates don't agree, if controls look wrong, or if batches dominate the signal, stop and fix upstream issues before statistics. Transparency beats guesswork every time; report what you check and what you decide.

Replicate agreement check (run‑to‑run similarity)

Inspect replicate similarity (e.g., pairwise correlations, PCA maps, replicate CV summaries) to ensure no single run dominates the signal. You're not hunting a magic cutoff here—look for patterns: one outlier dragging variance, a bait group splitting by run order, or negatives forming multiple clusters. If you remove a run or re‑process, record the reason and its impact on downstream comparisons; this is the kind of traceability reviewers reward.

Control sanity check: does IgG look like IgG?

IgG controls should resemble background spectra—not bait‑enriched samples. Beads‑only runs should surface matrix binders; KO/untagged should lack bait‑dependent signals. If the bait appears high in IgG, you likely have antibody specificity issues or a sticky target; pause and consult your wet‑lab protocol. Practical pitfalls and failure modes are summarized in the Endogenous Co‑IP‑MS protocol checklist and failure modes.

Batch effects: spot early, report transparently

Batches happen—instrument maintenance, column changes, different prep days. Label batches up front, explore whether they align with biology, and decide whether to stratify normalization or include batch terms downstream. Don't "iron away" batch structure so aggressively that you erase real enrichment. When in doubt, document the choice and its sensitivity.

Step 2 — Filtering: remove obvious contaminants without over‑cleaning

Filtering is pruning, not logging. Over‑filtering discards true interactors; under‑filtering drowns them. Aim for a background‑aware approach driven by your negatives and supported by contaminant knowledge bases.

Common contamination sources in IP‑MS

Keratins, serum albumins, proteolytic enzymes, and high‑affinity bead binders tend to show up across experiments. The contaminant repository CRAPome quantified just how frequent such proteins are across controls, enabling more informed decisions rather than blanket deletions—see CRAPome (Nat Methods, 2013).

Background‑aware filtering using negative controls

Instead of deleting a fixed list outright, compare each prey's behavior in bait runs to its distribution across negatives. Frequency‑aware ideas (e.g., FC‑A/FC‑B) weight prey that commonly appear in controls more cautiously, and probabilistic scoring (SAINT) directly models bait vs control abundance with uncertainty. Canonical references include SAINT probabilistic scoring (Nat Methods, 2011) and the CRAPome background frequency framework (Nat Methods, 2013).

Keep a "removed list" for transparency

Maintain a table of removed entries and reasons—common contaminant (with DOI citation), reverse/decoy, sample carryover, or insufficient evidence. Include it in supplements and mention it explicitly in Methods. Clear removal rationales are a hallmark of reproducible work.

Step 3 — Normalization: make intensities comparable across samples

Normalization corrects for sample load, IP efficiency, and instrument drift so that enrichment comparisons are meaningful. But it won't rescue a poor antibody or rewiring from a broken protocol—know its limits.

What normalization can and cannot fix

It can reduce technical scale differences and stabilize variance; it cannot fix bait present in negatives, eliminate missing‑not‑at‑random (MNAR) dropout, or reverse batch confounding. A useful heuristic: if normalization removes your known biology, it is too aggressive.

Practical normalization choices for IP‑MS

• Global alignment approaches (e.g., median/total intensity scaling, VSN‑like variance stabilization) are well‑benchmarked in label‑free proteomics and provide a reasonable first pass when enrichment spans a minority of proteins. See reviews such as Välikangas et al., Brief Bioinform, 2018 and comparative assessments like Graw et al., ACS Omega, 2020.
• Control‑ or anchor‑based alignment: when suitable internal references or anchor proteins exist, align groups relative to those anchors—but justify your choice and report sensitivity.
• Batch‑wise strategies: normalize within batch and reconcile across batches only after confirming that across‑batch scaling does not erase true effects.

Warning signs of over‑normalization

Known interactors lose separation from negatives after normalization; replicates tighten unrealistically while bait vs control differences shrink; volcano plots show widespread "tiny‑but‑significant" hits with minimal effect size—clues that the scale was distorted. Report these checks explicitly.

Step 4 — Missing values: handle them like a scientist, not a magician

Missingness is normal in IP‑MS—low abundance near detection limits, stochastic MS/MS, intensity thresholds, and enrichment‑driven presence/absence all contribute. Treat it as data with mechanisms, not holes to be patched.

Explain the pattern you see and what it implies for your choices; then back those choices with a citation.

Why missingness happens in IP‑MS

• MCAR/MAR processes (e.g., random sampling or intensity‑dependent MS/MS) and MNAR processes (e.g., prey present in bait but truly absent in negatives) often coexist.
• Enrichment itself creates asymmetry: a protein may be confidently present in bait and truly unobserved in negatives.

A comprehensive review of mechanisms and strategies is provided by Kong et al., Proteomics, 2022.

Two principled strategies (expressed plainly)

Prefer an observable‑set analysis when MNAR dominates—restrict to confidently observable conditions and state exclusions openly. When justified by data, use MNAR‑aware imputation (e.g., QRILC/MinProb‑style left‑tail models) and show sensitivity: with/without imputation results and any changes in BH‑FDR and volcano interpretation, as recommended by Kong et al., 2022.

What reviewers want to see

Clarity over cleverness. Describe the missingness pattern you observed, the assumptions you made, and how conclusions change under reasonable alternatives. Reserve aggressive imputation for cases where mechanisms support it.

Step 5 — Statistics: from "lists" to confident hits

Trust micro‑box: A hit is only defensible when effect size and FDR are reported alongside negative controls.

The comparison that matters: IP vs negative controls

Center your statistics on bait versus negatives. With the mixed‑controls narrative, treat IgG as the primary baseline; then re‑run key tests using beads‑only and KO/untagged (where available) to demonstrate robustness. Probabilistic interactome scoring such as SAINT models bait‑vs‑control abundance directly and outputs posterior probabilities for interactions—see Choi et al., Nat Methods, 2011 and Teo et al., J Proteomics, 2013 (SAINTexpress). Rank‑based frameworks like CompPASS (PNAS, 2009) and MiST (Curr Protoc Bioinf, 2015) emphasize abundance, reproducibility, and specificity.

Effect size + FDR: the pair you must report

Report log2 fold enrichment versus negatives alongside multiple‑testing‑adjusted p‑values. The Benjamini–Hochberg procedure remains the standard, balancing discovery and false positives across large test sets—originally introduced in Benjamini & Hochberg, JRSS‑B, 1995 and explained for omics practitioners in Diz et al., Brief Funct Genomics, 2010. Don't chase significance without magnitude: tiny fold‑changes at vanishing q‑values rarely make persuasive biology in IP‑MS.

How to keep thresholds transparent

Pre‑specify your decision logic (effect size + BH‑FDR), justify any context‑specific cutoffs, and include a short sensitivity analysis in supplements (e.g., alternate normalization; with/without MNAR imputation; IgG‑only versus IgG+beads‑only controls).

Step 6 — Outputs that reviewers trust (volcano, tables, narrative)

Results should be legible to both domain peers and statistical reviewers. Think "minimum viable manuscript package": one figure to communicate the signal, three auditable tables, and wording that states assumptions and sensitivity.

Volcano plot as a communication tool

Use volcano plots to situate results: x‑axis is log2 fold enrichment (bait vs negatives); y‑axis is –log10 adjusted p‑value (BH‑FDR). Show effect‑size and FDR threshold lines and label a few canonical interactors. Make it obvious in the caption that the comparison is to negatives.

How to annotate an IP‑MS volcano plot for publication: effect size, FDR threshold, negative control context, and key proteins.

The three tables every IP‑MS paper should have

Include these as main/supplementary tables and describe their logic in Methods.

• Hit list table schema (example):

• QC summary table: summarize replicate agreement, control sanity observations, batch labels, and missingness.
• Removed/filtered list: itemize contaminants and rationales, ideally with a DOI for each contaminant rationale (e.g., CRAPome frequency) to aid reviewers.

For interpretation context and follow‑up experiments, see why Western blot is not enough in 2026 reviewer standards.

Reviewer‑friendly wording templates

• "We pre‑specified our decision criteria as log2 fold enrichment versus negative controls paired with BH‑adjusted p‑values and report sensitivity to normalization and imputation choices."
• "Negative controls (IgG as primary; beads‑only and KO where available) were incorporated directly into enrichment comparisons; frequent contaminants were additionally down‑weighted using background frequencies from CRAPome."
• "We avoided fixed numeric acceptance cutoffs; instead, we report replicate agreement, control behavior, and batch annotations transparently, with detailed thresholds deferred to QC documentation."
• "An itemized removed‑list (common contaminants, reverse/decoys, technical artifacts) and a reproducibility package with parameter manifests are provided in line with community reporting guidance."

For accepted reporting practices and data standards, see the PSI community overview ‘Proteomics Standards Initiative at Twenty Years' (JPR, 2023).

What to ask your provider: gold‑standard analysis deliverables

You don't need a black box; you need artifacts you can hand to a reviewer with confidence.

Minimum deliverables

Expect a complete hit table (log2 fold enrichment vs negatives, BH‑FDR, and, if used, an interactome score such as SAINT/MiST/CompPASS), a QC summary (replicate agreement, control sanity, batch notes, missingness), and a removed/filtered list with rationales and contaminant references. The IP‑MS service guide: demo report, deliverables, NDA/IP describes how a demo package should look and what's included.

Gold‑standard deliverables

Ask for a short sensitivity analysis across reasonable choices (normalization options; with/without MNAR imputation; IgG‑only vs mixed controls), a background assessment summary (e.g., CRAPome‑style frequency weighting with literature anchors), and a reproducibility package (versioned reference files, parameter manifest, and Methods aligned with MIAPE/PSI guidance; see Proteomics Standards Initiative at Twenty Years (JPR, 2023)). For how to frame results for skeptical reviewers, the Case study blueprint for reviewer‑requested IP‑MS validation provides a practical path.

Red flags (briefly, avoid the list sprawl)

Deliverables that only include a flat protein list without enrichment versus negatives, omit QC/control descriptions, and lack threshold rationale or a removed list are not audit‑ready. Ask for explicit enrichment versus negatives, QC summaries, threshold justifications, sensitivity notes, and an itemized removed list.

Putting it all together (a reusable, reviewer‑ready workflow)

Here's the operating rhythm you can reuse across projects:

1. Assemble metadata and files; pre‑specify decision logic (effect size + BH‑FDR) and sensitivity plan; confirm mixed‑controls availability (design help: controls and replicates planning).
2. Run QC triage; fix replicate/control/batch issues or document why you proceed (see QC and acceptance criteria).
3. Filter with context: negatives and contaminant knowledge inform removals; keep a removed list.
4. Normalize to stabilize comparability, respecting batch structure; verify you haven't erased biology.
5. Handle missingness scientifically; prefer observable‑set analysis when MNAR dominates; if imputing, declare assumptions and show sensitivity.
6. Test bait vs negatives; report log2 fold enrichment and BH‑FDR; optionally include SAINT/MiST/CompPASS scores for interactome context.
7. Package outputs: annotated volcano; hit/QC/removed tables; Methods text using the reviewer templates above.

For broader context on experimental setup and troubleshooting, the Endogenous Co‑IP‑MS protocol checklist and failure modes is a helpful companion.

References (selected literature anchors)

• Interactome scoring and background frameworks: SAINT (Nat Methods, 2011); SAINTexpress (J Proteomics, 2013); CompPASS (PNAS, 2009); MiST protocol (Curr Protoc Bioinf, 2015); CRAPome (Nat Methods, 2013).
• Multiple testing and FDR: Benjamini & Hochberg (JRSS‑B, 1995); Diz et al. (Brief Funct Genomics, 2010).
• Missing data and imputation: Kong et al. (Proteomics, 2022).
• Normalization/batch handling: Välikangas et al. (Brief Bioinform, 2018); Graw et al. (ACS Omega, 2020).
• Reporting and standards: Proteomics Standards Initiative at Twenty Years (JPR, 2023).

Next steps

If you need an audit‑ready analysis package and demo materials to brief stakeholders, a specialist provider like Creative Proteomics can support QC‑first workflows, negative‑control‑centric statistics, and reviewer‑friendly deliverables while honoring NDAs and IP.

Author

CAIMEI LI
Senior Scientist at Creative Proteomics
LinkedIn: https://www.linkedin.com/in/caimei-li-42843b88/

Disclaimer: For research use only. Not for clinical diagnosis.